Cost effectiveness analysis in health care: contraindications
- PMID: 12386045
- PMCID: PMC1124387
- DOI: 10.1136/bmj.325.7369.891
Cost effectiveness analysis in health care: contraindications
Figures
References
-
- Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–1424. - PubMed
-
- Prosser L, Koplan J, Neuman P, Weinstein M. Barriers to using cost-effectiveness studies in managed care decision making. Am J Manag Care. 2000;6:173–179. - PubMed
-
- Litvak E, Long MC, Schwartz JS. Cost-effectiveness analysis under managed care: not yet ready for prime time? Am J Manag Care. 2000;6:254–255. - PubMed
-
- Hoffman C, Graf von der Schulenburg JM.for the EUROMET group. The influence of economic evaluation studies on decision making Health Policy 200052179–192. - PubMed
-
- Neuhauser D, Lewicki AM. What do we gain from the sixth stool guaiac? N Engl J Med. 1975;293:255–258. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical